1 October 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Investor Presentation via Engage Investor

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that the leadership team will host a live interactive presentation on the Engage Investor Platform on Tuesday 6 October 2026, at 3:00pm BST.

The presentation will be hosted by Dr Sotirios Stergiopoulos, Chairman; Sridhar Vempati, CEO and Stephen West, Non-Executive Director. The Company will provide an update on its clinical development programme and its strategic progress.

The Company welcomes all current shareholders and interested investors to join. Questions may be submitted in advance or at any time during the live presentation.

Investors can register with Engage Investor at no cost, follow the Company from their personalised investor hub and register their interest in attending here: https://engageinvestor.news/COIL_IP1026

-Ends-

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in an ongoing Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy focuses on generating evidence in selected tumour types, including ovarian and prostate cancer, to support potential pharmaceutical partnerships. Its broader pipeline includes a STAT-6 siRNA programme for immunology indications.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.

By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.

The Company is currently enrolling patients in dose-escalation cohorts evaluating the new lipid-based softgel formulation of AO-252. Phase I/II dose-expansion cohorts in ovarian and prostate cancer are planned to follow once the optimal dose has been established.

For more information, please visit: www.coiledplc.com and follow us on LinkedIn.